CRP and amyotrophic lateral sclerosis: During the NP001 ALS 6-month trials, patients with characteristics of those with innate immune activation (elevated inflammation markers such as CRP and neutrophils in patients ≤ 65 years of age) showed significantly better outcomes (changes in ALSFRS-R and VC scores) than placebo.